Keywords: Roche, R&D pipeline, Pesonalized medicines, Cancer drugs

Roche showcases R&D pipeline, with 72 NMEs and focus on personalized medicines

Article | 06 September 2012

Print This

At a London investor event this week, Swiss drug major Roche (ROG: SIX) presented an update on its strategy, which ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in